**3.3 Use of gadolinium-based contrast agents**

Three GBCAs (gadodiamide, gadoversetamide, and gadopentetic acid) are currently FDA-contraindicated in patients with GFR <30 mL/min/1.73 m2 . The American College of Radiology (ACR) recommends screening GFR of any patients with known or suspected renal impairment and advises against the use of any GBCA in patients with GFR <30 mL/min/1.73 m2 , suffering acute kidney injury, or requiring dialysis [30].
